低危非肌层浸润性膀胱癌主动监测失败患者的病理结局:膀胱癌意大利主动监测项目更新与结果
该前瞻性观察队列研究自2008年2月起在三级大学医院纳入167例复发性低级别非肌层浸润性膀胱癌患者,随访中181次主动监测事件有61次(33.7%)因细胞学阳性、肉眼血尿或肿瘤数目/大小增加而判定需治疗,失败者病理标本中20例未见恶性肿瘤;从首次经尿道电切至主动监测开始的时间与无复发生存呈负相关(HR 0.97,95%CI 0.96-1.00,p=0.024)。作者认为主动监测对于小的低级别pTa/pT1a复发性膀胱肿瘤可能是合理策略。
要点
- 181次主动监测事件中61次(33.7%)因细胞学阳性、肉眼血尿或肿瘤数目/大小增加而需治疗。
- 主动监测失败者的病理标本中20例未见任何恶性肿瘤。
- 首次电切至主动监测开始时间与无复发生存负相关(HR 0.97,95%CI 0.96-1.00,p=0.024)。
核心结论
- 主动监测对于表现为小的低级别pTa/pT1a复发性膀胱肿瘤的患者可能是合理的策略。
- 约30%被判定为主动监测失败的患者并未携带任何肿瘤性病变,这强化了主动监测的作用。
研究设计与样本
- 前瞻性观察队列研究,始于2008年2月,目前仍在进行,在三级大学医院开展。
- 纳入病理确诊为非肌层浸润性膀胱癌且在随访期间出现复发的患者,共167例。
- 主动监测方案为第一年每3个月、之后每6个月进行细胞学和诊室软性膀胱镜检查。
- 主要终点为未能继续主动监测患者的病理结果,次要终点为既往系列临床结果的更新。
- 采用描述性统计以及单变量和多变量比例风险Cox回归分析。
主要发现
- 共181次主动监测事件,其中61次(33.7%)因细胞学阳性(n=10)、肉眼血尿(n=11)、肿瘤数目增加(n=15)、肿瘤大小增加(n=17)或两者兼有(n=8)而被判定需要治疗。
- 主动监测的中位时间为12个月(四分位距4-26)。
- 主动监测失败者的病理标本中20例未见任何恶性肿瘤。
- 组织病理学识别出尿路上皮增生和水肿、黏膜下血管扩张、黏膜糜烂、息肉样膀胱炎、von Brunn巢增生和鳞状化生。
- 从首次经尿道电切至主动监测开始的时间与无复发生存呈负相关(风险比0.97,95%置信区间0.96-1.00;p=0.024)。
临床怎么用
- 作者认为主动监测对于表现为小的低级别pTa/pT1a复发性膀胱肿瘤的患者可能是合理的策略。
局限性
- 本研究缺乏针对失败且病理结果为阴性肿瘤性结局患者的统计学亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It has been shown that active surveillance (AS) is feasible and effective in a subset of patients with recurrent low-grade (LG) non-muscle-invasive bladder cancer (NMIBC). OBJECTIVE: To update a previous preliminary series and investigate pathological outcomes for patients who failed to remain on AS. DESIGN, SETTING, AND PARTICIPANTS: Prospective observational cohort study started in February 2008, and currently still active, at a tertiary university hospital, including patients with pathologically confirmed NMIBC who experienced recurrence during follow-up. INTERVENTION: AS monitoring consisted of cytology and in-office flexible cystoscopy every 3 mo for the first year, and every 6 mo thereafter. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was pathological results for patients who failed to remain on AS. The secondary outcome was an update of clinical results from our previous series. Data were complemented by descriptive statistical analysis and univariable and multivariable proportional hazards Cox regression. RESULTS AND LIMITATIONS: Overall, 167 patients were included. Of 181 AS events, 61 (33.7%) were deemed to require treatment because of positive cytology (n=10), gross haematuria (n=11), and increases in the tumour number (n=15), or size (n=17), or both (n=8). The median time on AS was 12 mo (interquartile range 4-26). Pathological specimens from AS failures did not show any malignancy in 20 cases. Histopathology identified urothelial hyperplasia and oedema, submucosal vascular ectasia, mucosal erosion, polypoid cystitis, von Brunn nest hyperplasia, and squamous metaplasia. The time from first transurethral resection to AS start was inversely associated with recurrence-free survival (hazard ratio 0.97, 95% confidence interval 0.96-1.00; p=0.024). The study lacks statistical subanalyses focusing on patients with failure and negative neoplastic pathological outcomes. CONCLUSIONS: AS might be a reasonable strategy in patients presenting with small LG pTa/pT1a recurrent bladder tumours. Approximately 30% of patients deemed to have AS failure did not harbour any neoplastic lesion, strengthening the role of AS. PATIENT SUMMARY: Patients with small low-grade pTa/pT1a recurrent papillary bladder tumours could benefit from an active surveillance protocol with no significant risk of pathological progression to muscle-invasive cancer.
引用
- Hurle R, Colombo P, Lazzeri M, et al. Pathological Outcomes for Patients Who Failed To Remain Under Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer: Update and Results from the Bladder Cancer Italian Active Surveillance Project. Eur Urol Oncol. 2018. PMID: 31158085. doi:10.1016/j.euo.2018.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。